login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
DENALI THERAPEUTICS INC (DNLI) Stock News
NASDAQ:DNLI - Nasdaq -
US24823R1059
-
Common Stock
- Currency: USD
14.465
-0.35 (-2.33%)
Summary
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
DNLI Latest News, Press Relases and Analysis
All
Press Releases
8 days ago - By: Zacks Investment Research
- Mentions:
BIIB
CRMD
DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26
9 days ago - By: Denali Therapeutics Inc.
Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
9 days ago - By: Denali Therapeutics Inc.
Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
15 days ago - By: Zacks Investment Research
- Mentions:
CPRX
ACAD
Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards?
20 days ago - By: Yahoo Finance
Denali Therapeutics Inc. (DNLI) Secures FDA Priority Review for First-Ever Brain-Penetrant Hunter Syndrome Therapy
a month ago - By: Yahoo Finance
BTIG Reiterates a Buy Rating on Denali Therapeutics (DNLI) With a $32 Price Target
a month ago - By: Denali Therapeutics Inc.
Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)
3 months ago - By: Zacks Investment Research
- Mentions:
MRNA
Why Is Denali Therapeutics (DNLI) Up 0.7% Since Last Earnings Report?
4 months ago - By: Zacks Investment Research
- Mentions:
SNY
BIIB
Denali Q1 Loss Wider Than Expected, Hunter Syndrome Drug in Focus
7 months ago - By: Benzinga
- Mentions:
JPM
Why Is Denali Therapeutics Stock Trading Higher On Wednesday?
4 months ago - By: Denali Therapeutics Inc.
Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome
4 months ago - By: Denali Therapeutics Inc.
Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome
5 months ago - By: Benzinga
What Happened To Denali Therapeutics Stock Wednesday?
5 months ago - By: Denali Therapeutics Inc.
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program
5 months ago - By: Denali Therapeutics Inc.
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program
6 months ago - By: Denali Therapeutics Inc.
Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
6 months ago - By: Denali Therapeutics Inc.
Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
7 months ago - By: Denali Therapeutics Inc.
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa
7 months ago - By: Denali Therapeutics Inc.
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa
7 months ago - By: Denali Therapeutics Inc.
Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™
7 months ago - By: Denali Therapeutics Inc.
Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
7 months ago - By: Denali Therapeutics Inc.
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)
7 months ago - By: Denali Therapeutics Inc.
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)
8 months ago - By: Investor's Business Daily
- Mentions:
BIIB
IONS
Denali Therapeutics Ratchets Up Losses On Misstep In ALS Treatment. Why The Game Isn't Over Yet.
8 months ago - By: Denali Therapeutics Inc.
Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
8 months ago - By: Denali Therapeutics Inc.
Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
9 months ago - By: Denali Therapeutics Inc.
Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s Disease
9 months ago - By: Denali Therapeutics Inc.
Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s Disease
10 months ago - By: Denali Therapeutics Inc.
Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
10 months ago - By: Denali Therapeutics Inc.
Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
Please enable JavaScript to continue using this application.